FGFR3 and neoplasm: In FGFR3 altered patients, the tumor immune microenvironment (TIME) has been found to have a generally non-T cell inflamed phenotype, but also relatively low immunosuppressive stromal features, which may allow a subset of patients to be responsive to ICI therapy [10–14].